Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: J Drug Deliv Sci Technol. 2020 Oct 6;61:102128. doi: 10.1016/j.jddst.2020.102128

Table 1.

Formulation compositions, processing parameters, and the observation of co-crystal formation during the HME process.

Formulation Processing Temp. (°C) Screw Speed (Rpm) Torque (%) Observation
1:1 TPH NAM (F1) 140 50 42–48 Eutectic peak was observed at 126.4 °C. Fine agglomerates
1:1 TPH NAM (F2) 150 50 45–51 Eutectic peak was observed at 126.4 °C. Fine agglomerates
1:1 TPH NAM (F3) 160 50 50–58 Eutectic peak was observed at 126.4 °C. Fine agglomerates
1:1 TPH NAM (F4) 170 50 50–58 Eutectic peak was observed at 126.4 °C with decreased intensity. Fine agglomerates
1:1 TPH NAM with 5% HPMCAS-MG (F5) 160 50 35–42 DSC thermogram with eutectic peak similar to the neat co-crystal was observed. Extrudate strands were produced
1:1 TPH NAM with 5% PEO (F6) 160 50 40–45 DSC thermogram with eutectic peak similar to the neat co-crystal was observed. Extrudate strands were produced
1:1 TPH NAM with 5% Kollidon VA-64 (F7) 160 50 25–30 Eutectic peak at 126.4 °C was disappeared and complete co-crystal formation at 174 °C was observed. Extrudate strands were produced